Abstract |
A hepatitis B virus vaccine demonstration project was conducted in southwest Alaska in 1981-1982 to determine the immunogenicity and efficacy of the vaccine. A total of 1630 susceptible persons in the Alaskan Native population were vaccinated with the recommended three-dose regimen of plasma-derived hepatitis B vaccine, and 94% demonstrated antibody to hepatitis B surface antigen (anti-HBs) at levels > or = 10 mIU/mL. After 10 years of follow-up, 76% of those immunized had anti-HBs levels > or = 10 mIU. During the 10 years following the first dose of vaccine, 13 study participants developed antibody to hepatitis B core antigen (10 vaccine responders, 3 nonresponders), and none developed sustained HBs positivity or had clinical hepatitis. These data suggest that immunization with hepatitis B vaccine continues to provide high levels of protection from clinical disease for at least 10 years.
|
Authors | R B Wainwright, L R Bulkow, A J Parkinson, C Zanis, B J McMahon |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 175
Issue 3
Pg. 674-7
(Mar 1997)
ISSN: 0022-1899 [Print] United States |
PMID | 9041341
(Publication Type: Journal Article)
|
Chemical References |
- Hepatitis B Antibodies
- Hepatitis B Surface Antigens
- Hepatitis B Vaccines
|
Topics |
- Adolescent
- Adult
- Alaska
- Child
- Female
- Hepatitis B
(prevention & control)
- Hepatitis B Antibodies
(analysis)
- Hepatitis B Surface Antigens
(immunology)
- Hepatitis B Vaccines
(therapeutic use)
- Humans
- Infant
- Inuit
- Male
- Middle Aged
- Time Factors
|